AU2014277568B2 - Anti-fibrogenic compounds, methods and uses thereof - Google Patents

Anti-fibrogenic compounds, methods and uses thereof Download PDF

Info

Publication number
AU2014277568B2
AU2014277568B2 AU2014277568A AU2014277568A AU2014277568B2 AU 2014277568 B2 AU2014277568 B2 AU 2014277568B2 AU 2014277568 A AU2014277568 A AU 2014277568A AU 2014277568 A AU2014277568 A AU 2014277568A AU 2014277568 B2 AU2014277568 B2 AU 2014277568B2
Authority
AU
Australia
Prior art keywords
fibrosis
kynurenine
compound
ornh
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014277568A
Other languages
English (en)
Other versions
AU2014277568A1 (en
Inventor
Aziz Ghahary
Ryan Hartwell
Ruhangiz T. Kilani
Yunyuan LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2014277568A1 publication Critical patent/AU2014277568A1/en
Application granted granted Critical
Publication of AU2014277568B2 publication Critical patent/AU2014277568B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014277568A 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof Active AU2014277568B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831404P 2013-06-05 2013-06-05
US61/831,404 2013-06-05
PCT/CA2014/000484 WO2014194407A1 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Publications (2)

Publication Number Publication Date
AU2014277568A1 AU2014277568A1 (en) 2016-01-28
AU2014277568B2 true AU2014277568B2 (en) 2019-09-19

Family

ID=52007349

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014277568A Active AU2014277568B2 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Country Status (14)

Country Link
US (1) US9737523B2 (cg-RX-API-DMAC7.html)
EP (1) EP3003298B1 (cg-RX-API-DMAC7.html)
JP (1) JP6473938B2 (cg-RX-API-DMAC7.html)
KR (1) KR102294405B1 (cg-RX-API-DMAC7.html)
AU (1) AU2014277568B2 (cg-RX-API-DMAC7.html)
CA (1) CA2914261C (cg-RX-API-DMAC7.html)
DK (1) DK3003298T3 (cg-RX-API-DMAC7.html)
ES (1) ES2978920T3 (cg-RX-API-DMAC7.html)
PH (1) PH12015502717B1 (cg-RX-API-DMAC7.html)
PL (1) PL3003298T3 (cg-RX-API-DMAC7.html)
RU (1) RU2726416C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201510003VA (cg-RX-API-DMAC7.html)
WO (1) WO2014194407A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201600015B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10779517B2 (en) 2017-01-31 2020-09-22 The Board Of Regents Of The University Of Oklahoma Animal wound model and methods of use
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
US20240226085A1 (en) * 2021-05-07 2024-07-11 Birchbiomed Inc. Kynrenine and derivatives thereof for treating atrophic scarring
CN119055650A (zh) * 2024-09-06 2024-12-03 上海市东方医院（同济大学附属东方医院） 犬尿喹啉酸在治疗慢性肝硬化中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
US20080161353A1 (en) * 2002-07-16 2008-07-03 Kevin Jeffrey Barnham 8-Hydroxy quinoline derivatives
WO2008087461A2 (en) * 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
AU2005306585A1 (en) * 2004-11-17 2006-05-26 Nuon Therapeutics Pty Limited A method of modulating B cell functioning
SMT202100248T1 (it) * 2012-06-15 2021-05-07 Conaris Res Institute Ag Composizione farmaceutica contenente acido nicotinico e/o nicotinammide e/o triptofano per influenzare positivamente il microbiota intestinale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
US20080161353A1 (en) * 2002-07-16 2008-07-03 Kevin Jeffrey Barnham 8-Hydroxy quinoline derivatives
WO2008087461A2 (en) * 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Also Published As

Publication number Publication date
CA2914261C (en) 2020-02-11
EP3003298A4 (en) 2017-03-22
NZ715579A (en) 2021-05-28
DK3003298T3 (da) 2024-06-17
KR102294405B1 (ko) 2021-08-25
RU2015156196A (ru) 2017-07-14
PL3003298T3 (pl) 2024-07-15
PH12015502717B1 (en) 2023-09-13
JP6473938B2 (ja) 2019-02-27
EP3003298B1 (en) 2024-03-20
EP3003298A1 (en) 2016-04-13
ZA201600015B (en) 2019-07-31
KR20160018676A (ko) 2016-02-17
BR112015030569A2 (pt) 2017-07-25
PH12015502717A1 (en) 2016-03-14
WO2014194407A1 (en) 2014-12-11
US9737523B2 (en) 2017-08-22
RU2015156196A3 (cg-RX-API-DMAC7.html) 2018-05-24
BR112015030569A8 (pt) 2020-01-07
ES2978920T3 (es) 2024-09-23
SG11201510003VA (en) 2016-01-28
AU2014277568A1 (en) 2016-01-28
US20160120857A1 (en) 2016-05-05
JP2016521695A (ja) 2016-07-25
CA2914261A1 (en) 2014-12-11
RU2726416C2 (ru) 2020-07-14

Similar Documents

Publication Publication Date Title
Lu et al. Nesfatin-1 functions as a switch for phenotype transformation and proliferation of VSMCs in hypertensive vascular remodeling
Chen et al. The antifibrotic and anti-inflammatory effects of icariin on the kidney in a unilateral ureteral obstruction mouse model
Li et al. Kynurenine increases matrix metalloproteinase-1 and-3 expression in cultured dermal fibroblasts and improves scarring in vivo
Luo et al. Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-β1/SMADs pathway
AU2014277568B2 (en) Anti-fibrogenic compounds, methods and uses thereof
Gu et al. Akebia Saponin D suppresses inflammation in chondrocytes via the NRF2/HO-1/NF-κB axis and ameliorates osteoarthritis in mice
Raman et al. Integrin-linked kinase signaling promotes cyst growth and fibrosis in polycystic kidney disease
Zanotti et al. Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-β1 treatment
Wang et al. Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells
Liu et al. Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice
Bai et al. Gypsophila elegans isoorientin-2 ″-O-α-l-arabinopyranosyl ameliorates porcine serum-induced immune liver fibrosis by inhibiting NF-κB signaling pathway and suppressing HSC activation
Ma et al. Nur77 ameliorates age‐related renal tubulointerstitial fibrosis by suppressing the TGF‐β/Smads signaling pathway
Kim et al. Hinokitiol increases the angiogenic potential of dental pulp cells through ERK and p38MAPK activation and hypoxia-inducible factor-1α (HIF-1α) upregulation
Yu et al. Irisin mitigates rheumatoid arthritis by suppressing mitochondrial fission via inhibiting YAP-Drp1 signaling pathway
US12006501B2 (en) Composition of drug targets and method of using thereof
He et al. GPRC5B protects osteoarthritis by regulation of autophagy signaling
Chen et al. Damage of uremic myocardium by p-cresyl sulfate and the ameliorative effect of Klotho by regulating SIRT6 ubiquitination
Liu et al. MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through inhibition of TGF-β-induced CTGF expression in human lung fibroblasts: Involvement of MKP-1 activation
Riaz et al. Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B
He et al. Pharmacological regulation of tissue fibrosis by targeting the mechanical contraction of myofibroblasts
Huang et al. A novel caffeic acid derivative prevents renal remodeling after ischemia/reperfusion injury
Sheng et al. Cholic acid mitigates osteoarthritis by inhibiting the NF-κB/PERK/SIRT1 signaling pathway
Wang et al. β-Hydroxybutyrate alleviates brain aging through the MTA1 pathway in D-galactose injured mice
NZ715579B2 (en) Anti-fibrogenic compounds, methods and uses thereof
Cheng et al. Role of TRIM59 in regulating PPM1A in the pathogenesis of silicosis and the intervention effect of tanshinone IIA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)